Name | Relationship | Address | Signature | Signature date | CIK |
---|---|---|---|---|---|
Mokari Atabak | Chief Financial Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY | /s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari. | 2025-06-04 | 0001678419 |
Id | Content |
---|---|
F1 | The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025 |
F2 | In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. |
F3 | Includes 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
F4 | Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. |
F5 | These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
F6 | The closing price on June 2, 2025 was used to calculate the withholding obligation. |
The power of attorney under which this form was signed is on file with the Commission.